BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27612858)

  • 21. A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.
    Cakir A; Gonul II; Uluoglu O
    Diagn Pathol; 2012 Oct; 7():145. PubMed ID: 23082819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers.
    Masili-Oku SM; Almeida BGL; Bacchi CE; Filassi JR; Baracat EC; Carvalho FM
    Breast; 2017 Feb; 31():34-39. PubMed ID: 27810697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Tumour Biol; 2014 Dec; 35(12):12255-63. PubMed ID: 25179840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers.
    Thike AA; Iqbal J; Cheok PY; Chong AP; Tse GM; Tan B; Tan P; Wong NS; Tan PH
    Am J Surg Pathol; 2010 Jul; 34(7):956-64. PubMed ID: 20495445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of basal cytokeratin expression in breast cancer.
    Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
    Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.
    Gazinska P; Grigoriadis A; Brown JP; Millis RR; Mera A; Gillett CE; Holmberg LH; Tutt AN; Pinder SE
    Mod Pathol; 2013 Jul; 26(7):955-66. PubMed ID: 23392436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study.
    Sousa B; Paredes J; Milanezi F; Lopes N; Martins D; Dufloth R; Vieira D; Albergaria A; Veronese L; Carneiro V; Carvalho S; Costa JL; Zeferino L; Schmitt F
    Histol Histopathol; 2010 Aug; 25(8):963-74. PubMed ID: 20552547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.
    Iqbal J; Thike AA; Cheok PY; Tse GM; Tan PH
    Histopathology; 2012 Oct; 61(4):652-9. PubMed ID: 22759273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer.
    Liu M; Tsang JYS; Lee M; Ni YB; Chan SK; Cheung SY; Hu J; Hu H; Tse GMK
    J Clin Pathol; 2018 Nov; 71(11):1007-1014. PubMed ID: 30099407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S
    Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytologic features of triple-negative breast carcinoma.
    Bonzanini M; Morelli L; Bonandini EM; Leonardi E; Pertile R; Dalla Palma P
    Cancer Cytopathol; 2012 Dec; 120(6):401-9. PubMed ID: 22833438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women.
    Yeong J; Thike AA; Ikeda M; Lim JCT; Lee B; Nakamura S; Iqbal J; Tan PH
    J Clin Pathol; 2018 Feb; 71(2):161-167. PubMed ID: 28735300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.
    Lakis S; Dimoudis S; Kotoula V; Alexopoulou Z; Kostopoulos I; Koletsa T; Bobos M; Timotheadou E; Papaspirou I; Efstratiou I; Aravantinos G; Karavasilis V; Zagouri F; Gogas H; Razis E; Pentheroudakis G; Christodoulou C; Pectasides D; Fountzilas G
    Anticancer Res; 2016 May; 36(5):2365-78. PubMed ID: 27127145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer.
    Cheung SY; Boey YJ; Koh VC; Thike AA; Lim JC; Iqbal J; Tan PH
    Breast Cancer Res Treat; 2015 Aug; 152(3):489-98. PubMed ID: 26123543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.